Pill Colors Play a Role in Medication Adherence
By HospiMedica International staff writers Posted on 17 Jan 2013 |
Changes in pill color increase the risk that patients will not complete their antiepileptic drug (AED) prescriptions, according to a new study.
Researchers at Brigham and Women's Hospital (Boston, MA, USA) designed a nested case-control study involving 11,472 patients who failed to refill a prescription for an AED within 5 days of the time they ran out of pills; the controls, 50,050 patients, had no refill delays and were matched to cases by sex, age, number of refills, and the presence of a seizure disorder diagnosis. The researchers evaluated the two refills preceding nonpersistence, and compared the odds of discordance among cases and controls. In all, the drugs dispensed had 37 colors and four shapes.
The researchers found that color discordance preceded 136 cases (1.2%) but only 480 controls (0.97%); shape discordance preceded 18 cases (0.16%) and 54 controls (0.11%). Within a seizure disorder-diagnosis subgroup, the risk of nonpersistence after changes in pill color was also significantly elevated. The researchers concluded that changes in pill color significantly increase the odds of nonpersistence, and urge a reconsideration of current regulatory policy that permits wide variation in the appearance of bioequivalent drugs. The study was published on December 31, 2012, in Archives of Internal Medicine.
“A patient taking five medicines, each produced by five generic manufacturers, theoretically faces over 3,000 possible arrays of pill appearances for what are, chemically and clinically speaking, the same drugs,” said lead author Aaron Kesselheim, MD, JD. “Those choices could confuse patients and result in poor adherence to therapy.”
“Subjecting patients to this risk is absolutely senseless and absurd. Generic medicines should be required to look like their brand-name counterparts,” commented Archives of Internal Medicine associate Editor Kenneth Covinsky, MD. “With all the hurdles patients face, how on earth can we justify confusing them by needlessly changing the appearance of their medicines?”
Related Links:
Brigham and Women's Hospital
Researchers at Brigham and Women's Hospital (Boston, MA, USA) designed a nested case-control study involving 11,472 patients who failed to refill a prescription for an AED within 5 days of the time they ran out of pills; the controls, 50,050 patients, had no refill delays and were matched to cases by sex, age, number of refills, and the presence of a seizure disorder diagnosis. The researchers evaluated the two refills preceding nonpersistence, and compared the odds of discordance among cases and controls. In all, the drugs dispensed had 37 colors and four shapes.
The researchers found that color discordance preceded 136 cases (1.2%) but only 480 controls (0.97%); shape discordance preceded 18 cases (0.16%) and 54 controls (0.11%). Within a seizure disorder-diagnosis subgroup, the risk of nonpersistence after changes in pill color was also significantly elevated. The researchers concluded that changes in pill color significantly increase the odds of nonpersistence, and urge a reconsideration of current regulatory policy that permits wide variation in the appearance of bioequivalent drugs. The study was published on December 31, 2012, in Archives of Internal Medicine.
“A patient taking five medicines, each produced by five generic manufacturers, theoretically faces over 3,000 possible arrays of pill appearances for what are, chemically and clinically speaking, the same drugs,” said lead author Aaron Kesselheim, MD, JD. “Those choices could confuse patients and result in poor adherence to therapy.”
“Subjecting patients to this risk is absolutely senseless and absurd. Generic medicines should be required to look like their brand-name counterparts,” commented Archives of Internal Medicine associate Editor Kenneth Covinsky, MD. “With all the hurdles patients face, how on earth can we justify confusing them by needlessly changing the appearance of their medicines?”
Related Links:
Brigham and Women's Hospital
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Latest Patient Care News
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
- Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients
- Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases
- Wearable Cardioverter Defibrillator System Protects Patients at Risk of Sudden Cardiac Arrest
- World's First AI-Ready Infrasound Stethoscope Listens to Bodily Sounds Not Audible to Human Ear